10-Q: Axogen Reports 12.9% Revenue Increase in First Quarter 2024, Advances BLA Submission

Axogen, Inc. announced a 12.9% increase in revenue for the first quarter of 2024, alongside progress in its Biologics License Application (BLA) for Avance Nerve Graft and the limited launch of Avive+ Soft Tissue Matrix.

Summary

• Axogen's revenue for the first quarter of 2024 reached $41.378 million, a 12.9% increase compared to $36.664 million in the same period of 2023.
• The company's gross profit increased by 14.5% to $32.620 million, up from $28.492 million in the first quarter of 2023.
• The increase in revenue was driven by a 5.3% increase in product mix, a 4.9% increase in unit volume, and a 2.6% increase in prices.
• Axogen reported a net loss of $6.635 million for the quarter, compared to a net loss of $7.074 million in the first quarter of 2023.
• The company had 1012 active accounts as of March 31, 2024, representing an increase of 1.8% year-over-year.
• Core accounts, defined as those purchasing at least $100,000 in the past twelve months, totaled 400, an increase of 14.3% year-over-year.
• Axogen anticipates completing the rolling BLA submission for Avance Nerve Graft in the third quarter of 2024, with potential approval in mid-2025.
• The company initiated a limited market release of Avive+ Soft Tissue Matrix in the first quarter of 2024 and plans a full launch in June 2024.
• Axogen believes its existing cash, cash equivalents, and investments, along with product sales, will fund operations for at least the next 12 months.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and progress on key product launches and regulatory approvals. However, the company is still operating at a loss and has some financial risks, which tempers the overall sentiment.

Positives

• Revenue increased by 12.9% year-over-year, indicating strong sales growth.
• Gross profit increased by 14.5% year-over-year, showing improved profitability.
• The number of active and core accounts increased, suggesting growing market adoption.
• The company is progressing with the BLA submission for Avance Nerve Graft, with a potential approval in mid-2025.
• The limited launch of Avive+ Soft Tissue Matrix is underway, with a full launch expected in June 2024.
• Axogen has sufficient cash to fund operations for at least the next 12 months.

Negatives

• The company reported a net loss of $6.635 million for the quarter, although this is an improvement from the $7.074 million loss in the same period last year.
• Cash and cash equivalents decreased by $13.390 million from the end of 2023, primarily due to operating activities.
• Total costs and expenses increased by 3.8% year-over-year, driven by increased compensation and professional services costs.
• Other expenses increased significantly due to higher interest expenses and changes in the fair value of derivatives.

Risks

• The company's products are subject to regulatory scrutiny, and failure to comply with requirements could impact commercial availability.
• The company is dependent on its processing facilities, and any disruption could harm operations.
• The company's debt includes a revenue participation agreement, which adds to interest expenses.
• The company is subject to legal proceedings, which could have a material adverse effect on its financial condition.
• The company's future capital requirements may depend on various factors, and there is no assurance that funding will be available on acceptable terms.
• The company is dependent on third-party suppliers for some of its products, and the loss of these suppliers could have a material adverse effect on the business.

Future Outlook

Axogen expects to complete the BLA submission for Avance Nerve Graft in the third quarter of 2024, with potential approval in mid-2025. The company also plans a full launch of Avive+ Soft Tissue Matrix in June 2024 and believes its existing cash and product sales will fund operations for at least the next 12 months.

Management Comments

• Management is pleased with the adoption of Axoguard HA+ Nerve Protector across multiple applications.
• Management is driving continued growth within the nerve protection category following the full launch of Avive+ Soft Tissue Matrix.
• Management continues to see strong interest in and adoption of the Resensation neurotization techniques for autologous and implant-based breast reconstructions.

Industry Context

Axogen operates in the medical device industry, specifically focusing on nerve regeneration and repair. The company's growth is driven by the increasing demand for solutions to peripheral nerve injuries. The launch of Avive+ Soft Tissue Matrix and the progress of the Avance Nerve Graft BLA are key developments that could enhance Axogen's competitive position in the market. The company's focus on surgeon education and patient activation is also a key factor in driving adoption of its products.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, Axogen's 12.9% revenue growth is a positive indicator in the medical device sector, where growth rates can vary significantly depending on the specific market segment.
• The company's gross margin of 78.8% is relatively high, suggesting a strong pricing strategy and efficient cost management compared to some medical device companies.
• The increase in active and core accounts indicates a growing market presence, which is a key metric for companies in the medical device space.
• The progress of the BLA for Avance Nerve Graft is a significant milestone, as regulatory approvals are critical for market access and can be a competitive advantage.
• Companies like Integra LifeSciences and Medtronic also operate in the regenerative medicine and nerve repair space, and Axogen's performance can be benchmarked against their growth and profitability metrics when available.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various claims, lawsuits, and proceedings in the ordinary course of business.
• Management believes that such claims are either adequately covered by insurance or otherwise indemnified, or are not expected to result in a material adverse effect on the company's financial condition, results of operations, or cash flows.
• However, it is possible that the company's results of operations, financial position, and cash flows in a particular period could be materially affected by these contingencies.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance, regulatory approvals, and potential capital raises.
• Employees may be impacted by changes in compensation, job security, and the company's overall performance.
• Customers (surgeons and healthcare providers) may benefit from the company's innovative products and solutions.
• Suppliers may be impacted by the company's purchasing decisions and supply agreements.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• Complete the rolling BLA submission for Avance Nerve Graft in the third quarter of 2024.
• Fully launch Avive+ Soft Tissue Matrix in June 2024.
• Continue to expand the customer base and sales force.
• Monitor and manage the company's financial position and cash flow.
• Continue to drive adoption of Resensation neurotization techniques.

Key Dates

Keywords

nerve regeneration, peripheral nerve repair, Avance Nerve Graft, Axoguard, Avive+ Soft Tissue Matrix, biologics license application, BLA, medical devices, tissue engineering, healthcare